# US 11,338,001 B2 · Probiotics for aggregation with disease-associated species in the oral cavity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,338,001 B2
- Document ID: US11338001B2
- Status: Granted
- Kind: B2
- Application number: 16/478,514
- Filed: 2018-01-17
- Published: 2019-12-05
- Granted: 2022-05-24
- Earliest claimed: 2017-01-18
- Assignees: Symrise AG; Probi AB
- Applicants: Symrise AG; Probi AB
- Inventors: Marcus Rudolf Götz; Kerstin Holmgren; Niklas Larsson; Bernd Fiebich; William Wade
- Web page: https://patentgrep.com/patent/US11338001B2

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23G 4/12: containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins (containing dairy products A23G4/16)
- A23G 4/123: {containing microorganisms, enzymes}
- A61K 8/99: from microorganisms other than algae or fungi, e.g. protozoa or bacteria
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/0058: {Chewing gums (non-medicinal aspects, preparing chewing gum A23G4/00; chewing gum for care of the teeth or oral cavity, e.g. with breath freshener A61Q11/00)}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23G: COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to certain microorganisms or mixtures thereof for use in the treatment and/or prevention of inflammation in the oral cavity, preferably for the treatment and/or prevention of gingivitis and/or peridontitis. In particular, the present invention relates to microorganisms or mixtures thereof for use as probiotic agents for forming co-aggregates with microorganisms associated with gingivitis and/or peridontitis. Furthermore, the present invention provides oral pharmaceutical compositions, oral care products or products for nutrition or pleasure comprising one or more of the probiotic microorganisms as active agents as well as a method of production thereof.

## Claims

### Claim 1

A method for treating gingivitis and/or periodontitis comprising orally administering to a subject a microorganism or a mixture of two or more microorganisms selected from the group consisting of Lactobacillus delbrueckii subsp. lactis LL-G41 (CCTCC M 2016652), Lactobacillus fermentum 35D (DSM 32130), Lactobacillus gasseri NS8 (NCIMB 11718), Lactobacillus salivarius NS 12 (NCIMB 8816), Streptococcus salivarius NS18 (CBS 142430), and Streptococcus salivarius NS19 (CBS 142431).

### Claim 2 (depends on 1)

The method of claim 1, wherein the microorganism or the mixture of two or more microorganisms is (an) attenuated or (a) dead microorganism(s).

### Claim 3 (depends on 1)

The method of claim 1, wherein the microorganism or the mixture of two or more microorganisms has an inhibitory activity on the growth of one or more disease-associated microorganisms selected from the group consisting of Porphyromonas gingivalis, Porphyromonas endodontalis, Tannerella forsythia, Filifactor alocis, Eubacterium saphenum, Parvimonas micra, and Lachnoanaerobaculum saburreum, and wherein the microorganism is Lactobacillus salivarius NS12 (NCIMB 8816).

### Claim 4 (depends on 1)

The method of claim 1, wherein the microorganism or the mixture of two or more microorganisms is additionally capable of treating inflammation in an oral cavity by inhibiting the release of one or more inflammatory factors selected from the group consisting of interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor (TNF), prostaglandin E2 (PGE2), isoprostanes, matrix metallopeptidase 9 (MMP9) and NF-κB, and wherein the microorganism or the mixture of two or more microorganisms is/are selected from the group consisting of Lactobacillus delbrueckii subsp. lactis LL-G41 (CCTCC M 2016652), Lactobacillus fermentum 35D (DSM 32130), and Lactobacillus salivarius NS1.2 (NCIMB 8816).

### Claim 5 (depends on 1)

The method of claim 1, wherein the microorganism or the mixture of two or more microorganisms forms co-aggregates with oral bacterial species selected from the group consisting of Porphyromonas gingivalis, Porphyromonas endodontalis, Tannerella forsythia, Filifactor alocis and Eubacterium saphenum.

### Claim 6 (depends on 1)

The method of claim 1, wherein the microorganism or the mixture of two or more microorganisms is orally administered to the subject in an oral composition, wherein the microorganism or the mixture of two or more microorganisms is present in the oral composition in a range from 0.01 to 100%, with respect to the total weight of the oral composition, and/or wherein the total amount of the microorganism or the mixture of two or more microorganisms is in the range from 1×103 to 1×1011 colony forming units (CFU).

### Claim 7 (depends on 6)

The method of claim 6, wherein the oral composition is selected from the group consisting of a toothpaste, a tooth gel, a tooth powder, a tooth cleaning liquid, a tooth cleaning foam, a mouth wash, a mouth spray, dental floss, a chewing gum, and a lozenge.